Vancomycin therapeutic drug monitoring: Is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for antibiotic assays questionnaire

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 5, 2002, Pages 713-718

  Tobin, C M ^a   Darville, J M ^a   Thomson, A H ^b   Sweeney, G ^c   Wilson, J F ^d   MacGowan, A P ^a   White, L O ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Questionnaire; Therapeutic drug monitoring; Vancomycin

Indexed keywords

VANCOMYCIN;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG USE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; KIDNEY DYSFUNCTION; MICROBIOLOGY; OTOTOXICITY; PATIENT CARE; PRACTICE GUIDELINE; QUALITY CONTROL; QUESTIONNAIRE; SAMPLE; UNITED KINGDOM; STANDARD;

DRUG MONITORING; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES; QUESTIONNAIRES; VANCOMYCIN;

EID: 0036848114     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf212     Document Type: Article

References (40)

1. Freeman, C. D., Quintiliani, R. & Nightingale, C. H. (1993). Vancomycin therapeutic drug monitoring: is it necessary? Annals of Pharmacotherapy 27, 594-8.
2. Geraci, J. E., Heilman, F. R., Nichols, D. R., Wellman, W. E. & Ross, G. T. (1957). Some laboratory and clinical experience with a new antibiotic, vancomycin. In Antibiotics Annual 1956-1957, pp. 90-106. Medical Encyclopedia Inc., New York, USA.
3. Geraci, J. E., Heilman, F. R., Nichols, D. R. & Wellman, W. E. (1958). Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis: preliminary report. Mayo Clinic Proceedings 33, 172-81.
4. Geraci, J. E. & Hermans P. E. (1983). Vancomycin. Mayo Clinic Proceedings 58, 88-91.
5. Cooper, G. L. & Given, D. B. (1986). Vancomycin: A Comprehensive Review of 30 Years Clinical Experience. Park Row Publishers, San Diego, CA, USA.
6. Rybak, M. J. & Boike, S. C. (1986). Monitoring vancomycin therapy. Drug Intelligence and Clinical Pharmacy 20, 757-61.
7. Felmingham, D. (1999). Glycopeptides: vancomycin and teicoplanin. In Clinical Antimicrobial Assays (Reeves, D. S., Wise, R., Andrews, J. M. & White, L. O., Eds), pp. 137-48. Oxford University Press, Oxford, UK.
8. MacGowan, A. P., Reeves, D. S. & Wise, R. (1999). Interpretation of antimicrobial assays. In Clinical Antimicrobial Assays (Reeves, D. S., Wise, R., Andrews, J. M. & White, L. O., Eds), pp. 1-9. Oxford University Press, Oxford, UK.
9. Matzke, G. R., McGory, R. W., Halstenson, C. E. & Keane, W. F. (1984). Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy 25, 433-7.
10. Rybak, M. J., Albrecht, L. M., Boike, S. C. & Chandrasekar, P. H. (1990). Nephrotoxicity of vancomycin alone and with an aminoglycoside. Journal of Antimicrobial Chemotherapy 25, 679-87.
11. Linder, N., Edwards, R., MeClead, R., Mortensen, M. E., Walson, P. & Koren, G. (1993). Safety of vancomycin with or without gentamicin in neonates. Neonatal Network 12, 27-30.
12. Barth, R. H. & DeVincenzo, N. (1996). Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney International 50, 929-36.
13. Bailie, G. R. & Neal, D. (1988). Vancomycin ototoxicity and nephrotoxicity. A review. Medical Toxicology and Adverse Drug Experience 3, 376-86.
14. Etling, L. S., Rubenstein, E. B., Kurtin, D., Rolston, K. V., Fangtang, J., Mar Raad, I. I. et al. (1998). Mississippi mud in the 1990s: Risks and outcomes of vancomycin toxicity in general oncology practice. Cancer 15, 2597-607.
15. Gendeh, B. S., Gibb, A. G., Aziz, N. S., Kong, N. & Zahir, Z. M. (1998). Vancomycin administration in continuous ambulatory peritoneal dialysis: the risk of ototoxicity. Otolaryngology and Head and Neck Surgery 118, 551-8.
16. Goetz, M. B. & Sayers, J. (1993). Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. Journal of Antimicrobial Chemotherapy 32, 325-34.
17. Vance-Bryan, K., Rotschafer, J. C., Gilliland, S. S., Rodvold, K. A., Fitzgerald, C. M. & Guay, D. R. (1994). A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. Journal of Antimicrobial Chemotherapy 33, 811-21.
18. Fauconneau, B., Favreliere, S., Pariat, C., Genevrier, A., Courtois, P., Piriou, A. et al. (1997). Nephrotoxicity of gentamicin and vancomycin given alone and in combination as determined by enzymuria and cortical antibiotic levels in rats. Renal Failure 19, 15-22.
19. Rybak, M. J., Abate, B. J., Kang, S. L., Ruffing, M. J., Lerner, S. A. & Drusano, G. L. (1999). Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrobial Agents and Chemotherapy 43, 1549-55.
20. Cantu, T. G., Yamamaka-Yeun, N. A. & Lietman, P. S. (1994). Serum vancomycin concentrations: reappraisal of their clinical value. Clinical Infectious Diseases 18, 533-43.
21. Moellering, R. C. (1994). Monitoring serum vancomycin levels: Climbing the mountain because it is there? Clinical Infectious Diseases 18, 544-6.
22. MacGowan, A. P. (1998). Pharmacodynamics, pharmacokinetics and therapeutic drug monitoring of the glycopeptides. Therapeutic Drug Monitoring 20, 473-7.
23. de Gatta, F. M., Calvo, V., Hernandez, J. M., Caballero, D., San Miguel, J. F. & Dominguez-Gil, A. (1996). Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with haematological malignancies. Clinical Pharmacology and Therapeutics 60, 332-40.
24. Zimmerman, A. E., Katona, B. G. & Plaisance, K. I. (1995). Association of vancomycin serum concentration with outcomes in patients with Gram-positive bacteremia. Pharmacotherapy 15, 85-91.
25. British National Formulary. (2001). British National Formulary, Vol. 42. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, UK.
26. Moellering, R. C., Krogstad, D. J. & Greenblatt, D. J. (1981). Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Annals of Internal Medicine 94, 343-6.
27. Matzke, G. R., McGory, R. W., Halstenson, C. E. & Keane, W. F. (1984). Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrobial Agents and Chermotherapy 25, 433-7.
28. Lake, K. D. & Peterson, C. D. (1985). A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 5, 340-4.
29. Brown, D. L. & Mauro, L. S. (1988). Vancomycin dosing chart for use in patients with renal impairment. American Journal of Kidney Diseases 11, 15-9.
30. Pryka, R. D., Rodvold, K. A. & Erdman, S. M. (1991). An updated comparison of drug dosing methods. Part IV: Vancomycin. Clinical Pharmacokinetics 20, 463-76.
31. Rice, T. L. (1992). Simplified dosing and monitoring of vancomycin for the burn care clinican. Burns 18, 355-61.
32. Pryka, R. D. (1994). Vancomycin serum concentration monitoring: a continued debate. Annals of Pharmacotherapy 28, 1397-9.
33. Saunders, N. J. (1994). Why monitor peak vancomycin concentrations? Lancet 344, 1748-50.
34. Catchpole, C. & Hastings, J. G. (1995). Measuring pre- and post-dose vancomycin levels-time for a change? Journal Medical Microbiology 42, 309-11.
35. Begg, E. J., Barclay, M. L. & Kirkpatrick, C. M. (2001). The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology 52, Suppl. 1, 35S-43S.
36. Karam, C. M., McKinnon, P. S., Neuhauser, M. M. & Rybak, M. J. (1999). Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 19, 257-66.
37. Fitzsimmons, W. E., Postelnick, M. J. & Tortorice, P. V. (1988). Survey of vancomycin monitoring guidelines in Illinois hospitals. Drug Intelligence and Clinical Pharmacy 22, 598-600.
38. Duffall, S. B., Chambers, S. T. & Begg, E. J. (1993). How vancomycin is used in Australasia - a survey. Australian and New Zealand Journal of Medicine 23, 662-6.
39. Anne, L., Hu, M., Chan, K., Colin, L. & Gottwald, K. (1989). Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. Therapeutic Drug Monitoring 11, 585-91.
40. Follin, S. L., Mueller, B. A., Scott, M. K., Carfagna, M. A. & Kraus, M. A. (1996). Falsely elevated serum vancomycin concentrations in hemodialysis patients. American Journal of Kidney Diseases 27, 67-74.